310 related articles for article (PubMed ID: 34919490)
1. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.
Tarantino P; Barroso-Sousa R; Garrido-Castro AC; McAllister SS; Guerriero JL; Mittendorf E; Curigliano G; Tolaney SM
Expert Rev Anticancer Ther; 2022 Feb; 22(2):141-153. PubMed ID: 34919490
[TBL] [Abstract][Full Text] [Related]
2. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
Howard FM; Villamar D; He G; Pearson AT; Nanda R
Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond.
Rizzo A; Ricci AD
Expert Opin Investig Drugs; 2022 Jun; 31(6):549-555. PubMed ID: 34793275
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
Steiner M; Tan AR
Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
8. Predictive biomarkers of response to immunotherapy in triple-negative breast cancer - state of the art and future perspectives.
Tancoš V; Blichárová A
Klin Onkol; 2023; 36(1):28-34. PubMed ID: 36868830
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
10. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
12. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.
Ren Y; Song J; Li X; Luo N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012144
[TBL] [Abstract][Full Text] [Related]
14. Refining patient selection for breast cancer immunotherapy: beyond PD-L1.
Kossai M; Radosevic-Robin N; Penault-Llorca F
ESMO Open; 2021 Oct; 6(5):100257. PubMed ID: 34487970
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
16. Tumor immune microenvironment and systemic response in breast cancer.
Kawaguchi K; Maeshima Y; Toi M
Med Oncol; 2022 Sep; 39(12):208. PubMed ID: 36175677
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.
Cejuela M; Vethencourt A; Pernas S
Curr Oncol Rep; 2022 Dec; 24(12):1801-1819. PubMed ID: 36255603
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
19. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
20. Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer.
Berner M; Hartmann A; Erber R
Adv Anat Pathol; 2023 May; 30(3):195-202. PubMed ID: 36418243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
